menu
    • menu

    Company profile for AntiCancer

    NEW Drugs in Dev: 2
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ANTICANCER INC is a biotechnology company based out of 7917 Ostrow Street San Diego, California, United States.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AntiCancerUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7917 Ostrow St San Diego, CA 92111
    Telephone
    Telephone
    858-654-2555
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.anticancer.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/anticancer-inc/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharmaresearch Gets FDA Nod For PRD-101 Nano Anticancer Ph1 Trial
    Pharmaresearch Gets FDA Nod For PRD-101 Nano Anticancer Ph1 Trial

    06 Feb 2026

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/pharmaresearch-receives-us-fda-clearance-to-initiate-phase-1-clinical-trial-of-nano-anticancer-drug-prd-101-302681109.html

    PR NEWSWIRE BIO
    06 Feb 2026
    Share Share
    Anticancer Announces its First Granted US Patent for Synthetic Lethal Approach
    Anticancer Announces its First Granted US Patent for Synthetic Lethal Approach

    09 Sep 2021

    // BIOSPACE

    https://www.biospace.com/article/anticancer-bioscience-announces-its-first-granted-us-patent-for-synthetic-lethal-approach-to-identifying-novel-cancer-treatments/?s=71

    BIOSPACE
    09 Sep 2021
    Share Share
    Anticancer Bioscience Appoints Leader in Oncology Drug Development
    Anticancer Bioscience Appoints Leader in Oncology Drug Development

    14 Jul 2021

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20210714005067/en

    BUSINESS WIRE
    14 Jul 2021
    Share Share
    Anticancer Bioscience Appoints Leader in Oncology Drug Development
    Anticancer Bioscience Appoints Leader in Oncology Drug Development

    14 Jul 2021

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20210714005067/en

    BUSINESS WIRE
    14 Jul 2021
    Share Share
    Patent Allowed for AntiCancer Inc.’s Oral Methioninase Which Targets
    Patent Allowed for AntiCancer Inc.’s Oral Methioninase Which Targets

    29 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210329005131/en/Patent-Allowed-for-AntiCancer-Inc.%E2%80%99s-Oral-Methioninase-Which-Targets-Cancer-Covid-19-Diabetes-Obesity-and-Aging

    BUSINESSWIRE
    29 Mar 2021
    Share Share
    AntiCancer Establishes Subsidiary CoronaCure to Develop Its Novel Therapeutic
    AntiCancer Establishes Subsidiary CoronaCure to Develop Its Novel Therapeutic

    22 Apr 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200422005140/en

    BUSINESSWIRE
    22 Apr 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search